The TriggerHappy Trial

Patient-reported Outcome After Corticoid Injection for Triggerfinger- a Randomized Controlled Study Between Two Injection Procedures and Between Corticoid Injection and Percutaneous Release

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04568993

Acronym

Triggerhappy

Enrollment

100

Registered

2020-09-29

Start date

2020-10-01

Completion date

2028-07-01

Last updated

2026-04-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Minimally Invasive Surgery, Trigger Finger, Trigger Thumb

Brief summary

This is a prospective randomized multicenterstudy focusing on PROMs after primary corticoid injection for triggerfinger with a comparison of two different injection techniques.

Detailed description

This study aims to compare two different methods of corticosteroid injections in patients with triggerfinger, and to study the effects of these injections by day-to-day self-assessment by the included study persons for four weeks. The patient assess: 1. Pain 2. Motion and 3. Triggering by VAS scale every day for four weeks.

Interventions

PROCEDUREProximal phalangeal level

Injection of methyl prednisone and lidocaine in the tendon sheet at the level of the proximal phalanx

DRUGVolar to the MCP-joint

Injection of methyl prednisone and lidocaine in the tendon sheet volar to the MCP-joint

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Intervention model description

Prospective randomized controlled trial

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

• 1. Triggering of one or more fingers and/or impaired active finger motion and/or pain during active finger motion 2. Localized tenderness volar to the MCP joint of the affected finger 3. The patient seeks treatment

Exclusion criteria

1. Previous treatment for triggerfinger in the finger to be treated 2. Impaired function of finger due to previous trauma/infection or other condition 3. Suspicion of other cause than triggeriinger/tendovaginitis 4. Patient not able to follow instructions

Design outcomes

Primary

Measure	Time frame	Description
Pain after injection	Four weeks	Visual analouge scale (VAS), range 0-10, where 0 indicates "no pain" and 10 "maximum pain"
Impairment of finger motion	Four weeks	Visual analouge scale (VAS), range 0-10, where 0 indicates "no impairment" and 10 "maximum impairment"
Triggering	Four weeks	Visual analouge scale (VAS), range 0-10, where 0 indicates "no trigger phenomenon" and 10 "Trigger phenomenon all the time/ locked finger"

Secondary

Measure	Time frame	Description
Quick-DASH	Four weeks	generic handquestionaire, 11 items, 0 means normal hand function, 100 most impaired function

Countries

Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 25, 2026